Conclusion
In conclusion, Sacubitril/Valsartan therapy in HFrEF patients is safe and moderately tolerated among the Pakistani population with stable hemodynamic parameters and significant improvement in left ventricular function and function class. Hence, it can be used as first line of treatment for the patients with HFrEF with a gradual up-titration regime over a 6 weeks period.